What are the side effects of retatrutide?

Side Effect Data from TRIUMPH Trials

TRIUMPH-1 and related trials reported the following adverse event rates across retatrutide doses:

Gastrointestinal (most common)

• Nausea: 40–50% across dose range (vs 15% placebo)
• Diarrhea: 25–30%
• Vomiting: 15–20%
• Constipation: 15–25%
• Abdominal discomfort: 10–15%
• Dyspepsia: 10–12%

Cardiovascular

• Heart rate increase: 5–10 bpm average across dose range
• Palpitations: 3–5%

Other

• Injection site reactions: 10–15%
• Fatigue: 8–12%
• Headache: 10–15%
• Hair thinning: 3–6%

Dose-Related Side Effect Patterns

4 mg maintenance

• Well tolerated for most users
• Side effects similar to tirzepatide at 10 mg
• Discontinuation rate ~10%

8 mg maintenance

• Moderate side effects
• Most manageable with protocol adjustments
• Discontinuation rate ~15%

12 mg maintenance

• More pronounced side effects
• Titration must be slow for tolerability
• Discontinuation rate ~20%

Why Side Effects Are Somewhat Higher Than Tirzepatide

Retatrutide's triple receptor agonism (GLP-1, GIP, glucagon) produces additional mechanisms beyond tirzepatide's dual agonism:

• Stronger gastric slowing
• Additional effects on gastric motility patterns
• Glucagon receptor activation affects hepatic glucose output
• Enhanced catabolic state increases metabolic rate

These mechanisms produce greater weight loss and metabolic effects but also greater side effect burden at equivalent exposures.

Specific Concerns

Pancreatitis risk

• GLP-1 class drugs carry theoretical pancreatitis risk
• Trial data didn't show significant elevation, but n is limited
• Monitor for severe abdominal pain radiating to back
• History of pancreatitis is a relative contraindication

Gallbladder issues

• Rapid weight loss increases gallstone risk
• Retatrutide's aggressive weight loss rate increases this risk vs slower-losing drugs
• Trial rates for gallbladder events: 1–3%
• Symptoms: right upper quadrant pain, especially after fatty meals

Thyroid concerns

• Class warning about medullary thyroid carcinoma (MTC) from rat studies
• Theoretical risk not confirmed in human use
• Personal or family history of MTC or MEN2 is a contraindication

Heart rate elevation

• Modest HR increase is expected (5–10 bpm)
• Significant increase (> 15 bpm sustained) warrants evaluation
• New palpitations or arrhythmia symptoms need cardiology input
• Pre-existing tachyarrhythmia is a caution area

Gastroparesis concerns

• Severe gastric delay can mimic or cause gastroparesis
• Extremely rare but serious
• Symptoms: persistent vomiting, inability to keep food down, food coming up hours after eating
• May require dose reduction or discontinuation

Hypoglycemia

• Low risk in non-diabetic users
• Higher risk in diabetic patients on insulin or sulfonylureas
• Dose of those medications typically needs reduction

Side Effect Management

For nausea

• Eat smaller, more frequent meals (5–6 per day)
• Avoid high-fat, high-sugar, highly processed foods
• Ginger tea or ginger supplements
• Avoid eating 2 hours before injection
• Prescribed anti-emetics (ondansetron) for severe cases
• Avoid alcohol during titration

For constipation

• Fiber supplementation (psyllium, methylcellulose)
• Hydrate aggressively
• Magnesium citrate 200–400 mg at night
• Daily walking

For diarrhea

• Hydrate with electrolyte solutions
• BRAT diet (bananas, rice, applesauce, toast)
• Loperamide short-term if needed
• Discuss probiotic options with provider

For vomiting

• Hold dose if persistent
• Prescribed anti-emetics
• Aggressive hydration
• Seek care if dehydrated

For injection site reactions

• Rotate injection sites
• Let alcohol dry completely before injecting
• Use fresh needles
• Ice briefly after injection if consistent irritation

When to Stop or Reduce

• Severe persistent GI symptoms affecting daily life
• Unable to maintain hydration
• Severe or prolonged vomiting
• Signs of pancreatitis or gallbladder issues
• Significant unexplained weight loss beyond expected
• Severe injection site reactions
• Significant heart rate issues or new palpitations
• Any severe allergic reaction

Long-Term Side Effect Concerns

Known

• Rapid weight loss related risks (muscle loss, gallstones, nutritional deficits)
• Heart rate elevation persistence
• Potential gastrointestinal adaptation effects

Theoretical (limited data)

• Thyroid neoplasia (class warning)
• Pancreatic outcomes over years
• Gallbladder function long-term
• Reproductive outcomes
• Bone density effects from rapid weight loss

Who Should Avoid Retatrutide

• Personal or family history of MTC or MEN2
• Active pancreatitis or severe pancreatitis history
• Active gastroparesis
• Pregnancy or planning pregnancy
• Severe GI conditions
• Active gallbladder disease
• Uncontrolled diabetes with significant complications
• Severe cardiac arrhythmias

Comparison to GLP-1 Class

Side effect burden ranking (highest to lowest)

1. Retatrutide (triple agonist)
2. Tirzepatide (dual GLP-1/GIP)
3. Semaglutide (GLP-1 only)
4. Orforglipron (oral GLP-1)
5. Liraglutide (GLP-1 daily)

The efficacy-side-effect ratio scales roughly together — more potent drugs produce both more weight loss and more side effects.

When Side Effects Are Worth It

• Significant obesity with comorbidities (type 2 diabetes, cardiovascular disease)
• Inadequate response to other GLP-1 class drugs
• Need for aggressive weight loss (BMI > 40, bariatric-avoiding)
• Manageable side effects with protocol adjustments

When to Prefer Gentler Alternatives

• Modest weight loss goals
• Previous severe GI reaction to other GLP-1 class drugs
• Cardiovascular concerns
• Lifestyle unable to accommodate significant GI symptoms

Bottom Line

Retatrutide's side effect profile is real and somewhat heavier than tirzepatide or semaglutide. GI effects dominate. Most are manageable with slow titration, protocol adjustments, and symptomatic management. Discontinuation rates in trials were 10–20% — meaning 80–90% of patients tolerated treatment. The efficacy-benefit ratio is favorable for patients with significant weight loss goals who can manage GI effects.

See the retatrutide guide. Related: dosage protocol, vs tirzepatide.